Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
That is the practical version. The rigorous version is longer and says the same thing.
Where I part company with post #61, and it is a narrow parting.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
Happy to be corrected if someone holds better data than mine.
Post #61 is the version of this I will quote in future. One addition.
My experience of tirzepatide titration schedules contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in the class, so the trial answers a narrower question than the headline implies.
This is the sort of thing the wiki should carry and currently does not.
Picking up post #65: that is the part I would want checked first.
Small correction to my own earlier position on tirzepatide titration schedules. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
I had written a reply contradicting post #65 and deleted it. Here is what survived.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Everything in post #65 holds. The case it does not cover is the one I have.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
Posted with less confidence than the sentence structure implies.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
This is the sort of exchange that makes the archive worth searching.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Post #70 put the caveat in the right place and I want to underline it.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
The arithmetic in post #72 is right; the assumption feeding it is the part to check.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
The mechanism is plausible, which is not the same as established.
The bit of tirzepatide titration schedules that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
That is one dataset and I would not build a rule on it.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
On post #79 — agreed on the reasoning, with one qualification.
The titration schedule has more steps than semaglutide's, which reflects the finer gradation used in the clinical programme rather than a pharmacological requirement for smaller steps.
Genuinely open to being wrong about this one.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Post #83 is right about the mechanism and I think understates the practical bit.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
The part I am sure of is shorter than the part I have written.
Reframing tirzepatide titration schedules slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
I had written a reply contradicting post #83 and deleted it. Here is what survived.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
It took me longer than it should have to see that.
Nothing to add on the substance. Thank you for taking the question at face value.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Taking post #87 at face value and following it one step further.
Adding what did not work for me on tirzepatide titration schedules, since the failures never get written up and they are half the useful information.